Nutritionists and obesity medicine specialists generally acknowledge that compounded semaglutide, when sourced from an FDA-registered compounding pharmacy and prescribed by a licensed provider, may offer a pharmacologically equivalent effect to brand-name formulations, though it is important to note that compounded products have not undergone the same FDA approval process as brand-name drugs
More obese participants saw an even greater percentage of weight loss, averaging 26.5% over the same period
Therefore, GLP-1 therapy should be viewed as a potential supportive factor rather than a primary intervention
Gradual, sustained weight loss may reduce that pressure over time
The effects can last from a few weeks to a few months, depending on individual metabolism and lifestyle
Research-only is the legal product framing: strictly for research purposes and not for human or animal consumption